New company BlueRock Therapeutics, funded by $225m of series A cash from Bayer AG and Versant Ventures, is based on a new stem cell platform and will have an initial focus on cardiovascular diseases and neurodegenerative disorders.
The stem cell platform at BlueRock has been assembled through a series of partnerships with academic and industry collaborators in...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

